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Abstract
Background: Nanocrystals have the potential to substantially increase dissolution rate, solubility with subsequent
enhanced bioavailability via the oral route of a range of poor water soluble drugs. Regardless of other issues, scale up
of the batch size is the main issue associated with bottom up approach.
Material and Methods: Smart nanocrystals of artemisinin (ARM) was produced relatively at large batch sizes (100,
200, 300 and 400ml) compared to our previously reported study by (Shah, et al., 2016). ARM
nanosuspensions/nanocrystals were characterised using zeta sizer, SEM, TEM, DSC, PXRD and RP-HPLC. The
nanosuspensions were finally subjected to in vitro antimalarial and antimicrobial activity.
Results: The average particle size (PS) for 400 ml batches was 126.5 ±1.02 nm, and the polydispersity index (PI) was
0.194 ± 0.04. The saturation solubility of the ARM nanocrystals was substantially increased to (725.4± 2.0 µg/ml)
compared to the raw ARM in water 177.4± 1.3 µg/ml and stabilizer solution (385.3± 2.0 µg/ml). The IC50 value of
ARM nanosuspension against P. vivax was 65 and 21 folds lower than micronized 19.5 ng/mL and unprocessed drug
(6.4 ng/mL) respectively. The ARM nanosuspension was found highly effective compared to unprocessed drug against
all the tested microorganism except E. coli, Shigella and C. albican.
Conclusion: The simple precipitation-ultrasonication approach was efficiently employed for fabrication of ARM
nanosuspension to scale up the batch size. Similarly, the solubility, antimalarial potential and antimicrobial efficacy of
ARM in the form of nanosuspension were significantly enhanced. Findings from this study can persuade research
interest for further comprehensive studies using animals model.
Keywords: Artemisinin, Nanocrystals, Antimalarial, Antimicrobial activity.
Introduction
Malaria was one of the most challenging diseases until middle of the 20th century in Western medicine. In
different parts of Europe and North America malaria was endemic at that time (Meshnick and Dobson, 2001; Tarning,
2016). About 10,000 malaria cases are reported annually in Europe and 1300 to 1500 in the United States (Taylor, et
al., 2012). Pyremethamine, choloroquine, mefloquine and halofantrine are well-established drugs used for the treatment
of this disease. Malarial parasites offered strong resistance to these drugs. Despite the fast development of new research
approach in science and technology, there seem to be little or no promising and effective malarial vaccines available
(Joshi, et al., 2008). From traditional Chinese medicine a new class of antimalarial drug (artemisinin) was derived. In
China for at least 2000 years the use of Artemisia annua has been reported for the treatment of haemorrhoids and fever
(Klayman, 1985). Artemesinin in addition to antimalarial effects is also found to have optimum antifungal and
antibacterial effects and is been tested on various bacterial cultures of Staphylococcus aureus, Pseudomonas
aerueginosa, Mycobacterium intracellulare and Escherichia coli (Sack, 1975).
In literature more than 40% of active pharmaceutical ingredients (APIs) coming from high thorough screening
have the tendency of suffering from poor aqueous solubility with subsequent low rate of dissolution, bio-availability
and hence erratic efficacy (Shegokar and Müller, 2010). To address the problem of poor solubility, multiple
approaches are being employed and among which nanoparticles are becoming a fast platform solution. The stability of
suspensions relies on the method of generating particle and associated formulation components (Khan, et al., 2013). To
control particle sizes and particle size distribution currently static mixer and impinging reactors have been reported
(David, 2001). In nanoprecipitation, nucleation is very key to be controlled for tailoring particle sizes and their
distribution (Hu, et al., 2011). A numbers of factors are responsible for controlling nucleation including supersaturation
level, mixing time, micro-mixing and mass transfer etc (Lonare and Patel). Irradiation has been known to be effective
for mixing, to accelerate molecular diffusion and have the immense intensity for mass transfer (Lonare and Patel).
Artemisinin is a poorly water soluble drug which causes the erratic absorption and poor bioavailability with
consequent less antimalarial effect. According to WHO If the M. falciparum develops resistance to the artemisinin and
its derivatives, there will be no alternative effective compounds to treat malaria over the next ten years (Organization,
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2006). The aims of the current study was to scale up the batch size of artemisinin nanosuspension, investigation of
physico-chemical stability, saturation solubility of the produced nanocrystals compared to its unprocessed and
micronized drug and finally to assess whether the artemisinin nanocrystals possess an enhance antimalarial and
antimicrobial efficacy compared its unprocessed drug (Raw artemisinin/ Standard Drug).
Materials and Methods
Artemisinin (ARM) was kindly given by Institute of Material Medica, China, Batch No: (110916), polyvinyl
alcohol (M. Wt 30,000-70,000) was purchased from Sigma Aldrich, (USA) batch No: (MKBR5960V),
dimethylformamide (DMF) (Batch No 1373199), were purchased from Sigma Aldrich, (USA).
Preparation and scale up of ARM nanosuspension
ARM nanosuspension was fabricated and scaled up from 20ml batch size to 100, 200, 300 and 400ml using
the optimized approach as reported in our previous work by shah et al., with modification in power and length of time
for ultrasonication (Shah, et al., 2016). Briefly, 10mg/ml artemisinin was dissolved in dimethylformamide (DMF) with
the final volume of 10ml, 20ml, 30ml and 40ml, respectively. Also 0.15% PVA (anti-solvent (aqueous) solutions
having final volume of 90, 180, 260 and 240 ml were prepared. The organic (Solvent) and aqueous (Anti-solvent)
solutions were filtered through 0.4 µm filter to ensure maximum clarity. Afterwards 10ml, 20ml, 30ml and 40 ml of the
solvent containing drug were injected in to (pre-cooled at 4°C) 90, 180, 260 and 240 ml of anti-solvent solution
containing (PVA) respectively, with simple stirring at 1500 rpm. The resulted precipitated artemisinin suspension was
followed by ultra- sonication at different ultrasonic input 200, 250 and 300 Watt for different length of time 15, 20, 25
and 30 min. The time of ultra-sonication burst was set to 3sec with a pause of 5sec between two ultra-sonication burst.
During fabrication of the temperature of the vial was controlled with ice cold water. After ultra-sonication at above
mentioned parameters, the particle size measurements were carried out using Zetasizer Nano-ZS instrument, and the
nanocrystals were subjected to characterization and in vitro antimalarial and antimicrobial activity.
Characterization of ARM Nanocrystals
Particle size Measurement
Malvern Zetasizer Nano-ZS dynamic light scattering (DLS) (Malvern Instruments, UK) was used to determine
the particle size of ARM nanocrystals in the form of nanosuspensions.
Zeta Potential Measurements
Malvern Zetasizer Nano-ZS dynamic light scattering (DLS) (Malvern Instruments, UK) was used to determine
the zeta potential of the produced ARM nanosuspensions. For zeta potential measurements samples were prepared
according to the method reported by S. Plakkot et al., (Plakkot, et al., 2011). The original samples of the produced
nanosuspensions were further diluted with the dispersion medium. One millilitre samples of nanosuspensions were
further diluted with 2 ml of the dispersion medium. All the samples were analysed in triplicate.
Scanning Electron Microscopy (SEM)
Scanning electron microscope (SEM) (Quanta 400 SEM, FEI Company, Cambridge U.K) was used to evaluate
the morphology of unprocessed (Raw) ARM. Photomicrographs of ARM were taken at different ranges of
magnifications. However, images of ARM obtained at 220X were more prominent and descriptive. The particles of
ARM were coated with gold prior to morphological studies.
Transmission Electron Microscopy (TEM)
To confirm the particle size of ARM nanocrystals transmission electron microscopy (TEM) (TEM-1200Ex,
Japan Electron optics laboratory corporation Japan) was used at 120KV. Nanosuspension of ARM was deposited onto a
grid of 200 mesh capper grid coated with formvar/carbon (code No; S162) followed by drying the samples at ambient
temperature. The samples were stained negatively by using 2% magnesium uranyl acetate solution due to low
conductivity.
Differential Scanning Calorimetry (DSC)
Differential Scanning Calorimetry (DSC) module thermal analysis instruments (Q2000 series, TA instrument
West U.K) was used to determine the melting point (M.P) and heat fusion of unprocessed and processed ARM (400 ml
batch size). The instrument was calibrated with 99% indium having melting point 156.6°C and zinc with melting point
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419.5°C. Then under the stream of nitrogen gas the unprocessed and processed sample of artemether was then scanned
at a flow rate of 50 ml/minute with temperature ranging 25°C -200°C.
Powder X-Ray Diffraction Studies (PXRD)
The crystallinity of raw and processed ARM previously was recovered from nanosuspension by centrifugation
at 16000 rpm for 60 minutes and drying at ambient temperature was determine by using powder X-ray diffraction
(Bruker D-8 powder diffractometer, Brukes, Kahsruhi, Germany). Samples were scanned over the range 5-500 2Ɵ at 
rate of 10 2Ɵ /min, at wave length 1.542Ǻ with I mm Slit by using copper Kɑ as a radiation source in silicon-well 
sample holder. The PXRD was calibrated with corundum standard.
Solubility Studies
Solubility study of ARM nanocrystals was carried out by using the reported centrifugation method (Liu, et al.,
2011; Thakkar, et al., 2011; Van Eerdenbrugh, et al., 2010). For the nanosuspension, approximately 1.5ml of the
nanosuspension was filled in 1.5ml centrifugation tube and kept for 24 hrs followed by centrifugation at 1600 rpm for 1
hr using a sigma centrifuge (Scientific Lab supplier, Model: Sigma 0II5982IIII). To make sure complete solubility of
the produced nanocrystals the supernatant layer was taken and filtered through 0.02 µm filter (Syringe Filter: 20 nm,
Whatmananotop, Germany). The filtrate was analysed for the ARM contents by RP-HPLC, Waters 2695, system
connected to a UV detector and Ultra II TM C18 5µm 250×4.6mm column. The samples were analysed using modified
method as reported in reference (Kakran, et al., 2010). Solubility study of unprocessed ARM in pure water and
stabilizer solution 0.15% w/w PVA was also carried out to evaluate the effect of nanocrystals on saturation solubility of
ARM. Sufficient quantity of ARM in pure water and stabilizer solution was put in vials and sonicated for two hours
followed by the same procedure mentioned for nanocrystals.
Stability Studies
Physico-chemical stability of nanosuspensions been reported to be a major issues (Khan, et al., 2013). Owing
to increased surface free energy of the produced nanocrystals which can potentially lead to their altered physico-
chemical attributes. It is therefore important to carry out physico-chemical stability studies on the produced ARM
nanosuspensions. Physical stability of the produced ARM nanosuspensions was monitored by measurements of the
particles sizes and zeta potential values. However, the chemical stability was assessed by determination of the active
contents of ARM for seven days. The produced nanosuspensions were evaluated for their respective active contents
using the reported modified method of Kakran et al., (Kakran, et al., 2010). In addition, the ARM nanosuspension
(batch size 100 ml) was subjected to long term 90-day stability studies and stored at refrigerated conditions 2-8°C,
room 25°C and 40°C. The aims of this study were to determine the extent of particle growth through aggregation and
Ostwald ripening. The particles size measurements of the ARM stored samples were carried out for 3 months at regular
intervals 0, 10, 15, 30, 45, 60, 75 and 90 days by using DLS.
In vitro antimalarial activity
In vitro antimalarial activity of artemisinin (ARM) nanosuspension (processed), its unprocessed (Raw) and
micronized drug were performed against P. vivax. The specie was previously identified by trained microbiologist of
Teaching Hospital (Hayat Abad Medical Complex, Peshawar, Pakistan) using simple microscopic techniques. The
plasmodium culture was maintained as described by Trager and Jensen 1976 (Trager and Jensen, 1976). Stock solutions
of the ARM were prepared in solvent as described by Wahajuddine et. al (Trager and Jensen, 1976). The concentration
of ARM nanosuspension and its unprocessed and micronized drug were in range of 1 to 70 ng/mL. The culture (P.
vivax2-3% and hematocrit 2-3%) was exposed to various concentrations of the processed, unprocessed and micronized
ART for 72 hrs (37 °C, 5 % CO2). To each well Lytic buffer comprised on (20 mM Tris pH 7.5, 5 mM EDTA, 0.008%
saponin, and 0.08% triton X-100) and sybergreen-I was added followed by incubation for 3 hrs in dark at room
temperature. Parasites in the thin films was counted against 250 erythrocytes each. The experiment was performed in
triplicate and the mean parasitemia was calculated. The mean parasitemia in the drug-free control wells was served as
the parameter of optimum and relative growth inhibition in the drug wells and was calculated on the basis of formula as
suggested by Fidock et al (2004) (Fidock, et al., 2004). All the plates were read under fluorescence and IC50 was
determined.
Preparation of Bacterial and Fungal Cultures
Strains of gram positive (Staphylococcus aureus and Bacillus subtilis), gram negative bacteria (Escherichia
coli, Salmonella sp) and Candida albicans were cultured respectively on Nutrient agar and Sabouraud Dextrose Agar
(SDA). The produced cultures were then tested for antimicrobial effects keeping the standard environmental conditions.
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Antimicrobial Disk Diffusion Assay
The culture media of Nutrient agar and Sabouraud Dextrose Agar (SDA) were prepared and microbes were
cultivated by spreading technique using the method reported by Suganthi et al., (Appalasamy, et al., 2014). For negative and
positive controls filter paper discs impregnated with 1  L of polyvinyl alcohol (PVA) solution in water and streptomycin
were used, respectively. Artemisinin nanosuspensions 400 ml batch size and unprocessed drug were impregnated on the filter
paper discs accordingly. The produced cultures were then incubated keeping the standard environmental conditions. During
the incubation period of 48h, the diameters of the zones of inhibition were measured every six hours. All the tests were
performed in triplicate.
Minimum Inhibition Concentration (MIC) Measurement
Minimum inhibition concentration (MIC) was determined for each microbe based on the least concentrations of
artemisinin nanosuspensions (processed) and unprocessed (Raw). A serial dilution of artemisinin nanosuspensions and it
unprocessed drug was done using the sample in concentration 0.1mg/ml to 3mg/ml. On each plate of tested microbes six disks
of all the six concentrations were impregnated. All the test was done in triplicates. The Minimum bactericidal concentration
(MBC) value was determined by sub culturing the test dilution (which showed no visible turbidity) on to freshly prepared
nutrient agar media. The plates were incubated further for 18-42 h at 37 °C. The highest dilution that yielded no single
bacterial colony on the nutrient agar plates was taken as MBC.
Statistical Analysis
All the data were run in triplicate and results were subjected to statistical analysis using statistics 8.1. Mean values
were compared using ANOVA followed by Tukey's post hoc test. The difference was considered as significant at P < 0.05.
Results and Discussions
Preparation of Artemesinin nanosuspensions.
The batch size of ARM nanosuspensions was successfully increased to 400 ml. The initial particle size of ARM
unprocessed drug was confirmed by using SEM, which was found to be about 200 µm (Figure 1 A). The particle size (PS)
and polydispersity index (PI) values of the produced ARM nanosuspensions using simple stirring and combined approach
(Simple stirring) using PVA solution (Anti-solvent) 0.15% pre-cold at 4°C, are shown in Table 1. Simple stirring at 1500 rpm
was sufficient to produce the PS below 500 nm for all the samples. The minimum PS 126.5 ±1.02 nm and PDI 0.197±0.09 for
400 ml batch was achieved at ultrasonication input of 300 Watt within 30 minutes, The PS of nanocrystals was also
confirmed using TEM (Figure 1B). Similarly, by further increase in the power inputs and time for fabrication no substantial
decreased was observed in the PS and PI. However, for effective micromixing the stirring speed, ultrasonication power input
and time for ultrasonication was slightly increased (Table 1). The results demonstrated that by increasing the batch sizes no
substantial increased was observed in the PS and PI from the previously reported particle size which was 98.77 ±1.05nm
having PI 0.186±0.01 (Shah, et al., 2016). Therefore, this technology was effectively applied to scale up from 20 ml to 400 ml
batch size for fabrication of ARM nanosuspension. During the physical stability studies for 90 days it was found the
nanosuspensions stored at 2-8°C (Figure 2A) and 25°C (Figure 2B) was most stable compared to sample stored at 40°C
(Figure 2C). Also, the percent recovery of active contents was maximum 97.02± 2.30, which shows both efficiency of the
technology and stability of the drug as well (Table 2). Furthermore, by controlling the key parameters like concentration of
stabilizer, ultrasonic inputs, length for fabrication it could be possible to scale up this novel antimalarial drug for commercial
use in the form of nanosuspension.
Zeta Potential
The values of zeta potential of ARM nanosuspensions were found to be within the reported range ±20 mV as
presented and no significant difference was observed between tested formulation. The zeta potential results of 100 ml and 400
ml batch was found to be ±24.6 mV and ±25.1 mV respectively. The results demonstrated that PVA alone is sufficient to
stabilize nanosuspensions (Figure 3). This polymers has been reported previously for stabilization of drug nanocrystals using
bottom up approach (Xia, et al., 2010). Measurements of zeta potential have also been reported to predict physical stability of
formulated nanosuspensions. The zeta potential measurements depend both on surface of the drug particles and composition
of the stabiliser medium. A range of zeta potential values have previously been reported to give stable nanosuspensions,
which include ±30 mV and ±20 mV for electrostatically and sterically stabilised systems, respectively (Jacobs and Müller,
2002; Yang, et al., 2008). In addition a minimum zeta potential value of ±20 mV has been proposed for stability of
nanosuspensions where both ionic and non-ionic polymers and surfactants have been used as stabilizers (Ali, et al., 2009).
Solubility Studies
Solubility profile of artemesinin (ARM) nanocrystals and unprocessed ARM in pure water and stabilizer (polyvinyl
alcohol) solution has been shown in (Figure 4) The solubility of ARM nanocrystals was found to be 752.4 ± 2 µg/mL, an
almost 3.0-fold and 6-fold increase compared to the solubility of unprocessed ART in stabilizer solution 358.3± 2.0 µg/mL
and pure water 171.4± 1.3 µg/mL. Owing to increased surface area of the produced nanocrystals, a significant difference
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(P<0.001) was observed in solubility of the processed ARM compared to the solubility in water and stabilizer solution. There
has been previously reported that water soluble polymers and surfactants (HPMC, PVP and SLS) can increase solubility of
drug compounds (Aziz, et al., 2012; Leuner and Dressman, 2000). We also observed an increase in solubility of ARM in
stabilizer solution (PVA). The nanocrystals have however substantially increased the saturation solubility indicted that
solubility of ARM has been purely increased because of small particle size of the particles not due to the polymers.
Figure 1: (A) Scanning electron micrographs of unprocessed artemisinin, (B) transmission electron micrographs of
artemisinin nanocrystals
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Figure 2: Stability of artemisinin nanocrystals in term of monitoring the particle size and polydispersity index at
various time points on storage at, (A) 2-8°C, (B) 25°C, (C) 40°C.
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Figure 3: Zeta Potential of artemisinin nanosuspension.
Figure 4: Solubility studies of artemisinin nanocrystals, unprocessed artemisinin in pure water and in stabilizer
solution. Each bar represents mean ± SEM. One way ANOVA followed by post hoc Tukey's test. ***P < 0.001.
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Figure 5: DSC profile of processed and unprocessed artemisinin particles.
Figure 6: P-XRD patterns of processed and unprocessed artemisinin particles.
Table 1: Mean particle size (PS) of artemisinin in nanometre (nm) scale and particle size distribution (PDI), using
simple precipitation and ultra-sonication techniques.
(Values are expressed as mean ± SEM)
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Table 2: Chemical stability studies of Artemisinin nanosuspensions for seven days.
Values are expressed as mean ± SD (Standard Deviation).
Table 3: Comparative antimicrobial activity of artemisinin nanosuspension (mg/ml) and Unprocessed drug using
streptomycin (mg/ml) as positive control and PVA in water as negative control by disk diffusion assay. (a, b, c analysis
of variance)
Values in each column are significantly different (P<0.05)
Table 4: MIC and MBCs of artemisinin unprocessed drug and artemisinin nanosuspension.
Stability
Studies
Chemical Stability of Artemisinin Nanocrystals (% active contents± S.D)
Day-0 Day-1 Day-2 Day-3 Day-4 Day-5 Day-6 Day-7
Chemical
Stability
97.02±
2.30
96.70±
3.20
96.35±0.01
96.03±
0.25
94.75±
0.13
94.23±
0.12
94.97
±0.01
93.55 ± 0.21
Microbes
Zone of Inhibition (mm)
Unprocessed
Artemisinin
Nanoformulation
Artemisinin +Ve Control 6 ±0.00-Ve Control
B. Subtilis 1.3 ± 0.91 b 2.13a ± 0.76 a 1.4b± 0.37 b -
Streptococci 1.9 ± 0.52 b 3.86 ± 0.25 a 1.60 ± 0.42 b -
Staphylococcus 2.33 ± 0.91 b 4.5 ± 0.71 a 2.11 ± 0.67 b -
E. coli - - 3.5± 0.17 -
Salmonella 1.2 ± 0.15 b 2.1 ± 0.23 a 1.4 ± 0.33 b
Shigella - - -
C. Albican - - 8.78± 0.81
A. flavus 3.1 ± 0.15 c 5.6 ± 0.88 b 11.20± 1.11a
A. niger 2.6 ± 0.61 c 4.9 ± 0.20 b 9.12 ± 0.93 a
Microbes
MIC and MBC (mg/ml)
MIC values of
Artemisinin
MBC values of
Artemisinin
Unprocessed Nanosuspension Unprocessed Nanosuspension
B. Subtilis 0.87 0.39 2.1 0.55
Streptococci 0.71 1.53 2.21 2.67
Staphylococci 0.58 0.20 1.32 0.47
Salmonella 0.76 0.22 1.66 0.36
A. flavus 0.35 0.19 0.87 0.41
A. niger 0.71 0.33 1.19 0.73
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Dsc And P-Xrd Studies
Crystallinity of the processed artemisinin was assessed by using DCS and P-XRD, which were identified to be
crystalline in nature. A single sharp endotherm was observed for both the nanocrystals and raw ARM having slight
reduction in the melting onset temperature (Tonset) and in the melting peak maximum, of the nanocrystals compared to
raw ARM. Also, dropped in heat of fusion for nanocrystals was observed (Figure 5). In P-XRD studies both
nanocrystals and raw artemisinin produced sharp x-ray chromatograms which confirmed the crystalline nature of the
produced nanocrystals (Figure 6). This decreased in heat of fusion is due to the adsorbed polymer/stabilizer(s) on the
nanocrystals surface in trace amount (Valleri, et al., 2004). Also, this could be because of the low packing density in
case of nanoparticles. In P-XRD studies there was observed that intensity of the produced nanoparticles reduced,
broadened and disappearance of some peaks also occurred. Due to particle size broadening effect, the peak for ARM
nanoparticles was slightly broadened, which is the key to attain low particle size (Khan, et al., 2014).
In vitro antimalarial activity
Artemisinin (ARM) showed significant (P<0.05) results against P. vivax at a very low concentration 0.3
ng/ml. The IC50 value of ARM nanosuspension was 65-fold lower than the IC50 value of micronized 19.5 ng/mL and 21
fold lower than the IC50 value of the unprocessed 6.4 ng/mL drug. This unique interaction of nanoparticles with
biological system along with increased saturation solubility could be responsible for enhanced effectiveness.
Antimicrobial assay
Table 3 shows that ARM nanosuspension has strong effect against gram positive bacteria compared to the
unprocessed ARM and positive control, whereas no significant difference was observed in the effects of unprocessed
ARM and standard drug. However, both unprocessed and nanoformulation were found inactive against gram negative
bacteria except the positive control. Both the unprocessed and nanoformulation showed no activity against E-coli,
Shigella and Candida albican, while the positive control was found active against these microorganisms. These results
clearly indicated that the processed nanoformulation was found highly effective and a significant difference was
observed among the values of unprocessed ARM, nanoformulation of ARM and positive control against Aspergillus
flavus and Aspergillus niger. Table 4 shows the values of MIC of unprocessed ARM which were found less 0.58 mg/ml
in case of gram positive bacteria whereas 0.76mg/ml value was recorded against Salmonella. The produced ARM
nanocrystals were found highly effective against gram positive bacteria, Shigella and both of the tested fungus. In case
of MBC in general a significant high value was recorded as compared to MIC (Table 4). It was noted that ARM
nanocrystals were highly effective against bacteria and fungus as compared to the unprocessed ARM in term of MBC.
The inability of ARM nanosuspension to inhibit the C. albican was also reported by Galal et al., (Galal, et al., 2005).
Different strains of bacteria have different cell permeability and which play a key role in te rate of large molecules
penetrations (Lambert, 2002). Nanoparticles especially in submicron size (100 nm) have unique physicochemical
properties including large surface to mass ratio, ultra-small size, high reactivity and unique interactions with biological
systems (Zhang, et al., 2008).
Conclusion
This comprehensive study demonstrated that by controlling the process conditions using this technology, the
batch size for production of stable nanocrystals can be successfully increased without any significant changes in the
mean PS and PI. In addition, this technology can effectively produce large quantity of the ARM in the form of
nanoformulations which could potentially be commercialised with a low dose while having maximum therapeutic
potential. It will be a benefit to minimize the dose related toxicity and most importantly dose related resistance
problems of this drug due to erratic bioavailability issues. Furthermore, production of stable ARM nanocrystals in large
quantity can lead to established marketed products which in the very low dose will continue to improve the treatment of
microbial infections, especially in life-threatening diseases like malaria.
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